DocumentsDate added
Original article
Jayesh Warade MD1,*,Aparna Pandey PhD2
Affiliation:-
1Meenakshi Mission Hospital and Research Centre, Madurai, India
2Apollo Specialty Hospital, Madurai, India
The name of the department(s) and institution(s) to which the work should be attributed:
Meenakshi Mission Hospital and Research Centre, Madurai, India
Address reprint requests to
Dr. Jayesh Warade
F-4, 2nd Floor, Meenu Enclave,
T. M. Nagar, Melur Road, Madurai, 625107 Tamilnadu, India
Article citation:
Warade J,Pandey A. Diurnal Variation of TSH: Factor Affecting Interpretation of Test. J Pharm Biomed Sci.2014;04(09):776-780. Available at www.jpbms.info
ABSTRACT
Background: TSH test is the most common hormonal test prescribed in clinical set up. A lot of variations are noted in TSH value if the sample is collected at different times of the day. The interpretation results may lead to misclassification of patients into hypo, hyper or euthyroid category. Here in this study, we have studied the effect of time of sample collection - fasting and non-fasting state and at different time of the day. Material Methods: Total numbers of 227 subjects were included in the study. Three plain samples were collected from each patient: first at 6:00 am fasting sample; the second sample at 12:00 pm and third sample was collected on special request at 18:00 pm. The age group included was 25 - 45 years, both male and female subjects were included. Results: The data obtained is analysed using one way ANOVA test and it is found that there is a significant difference in TSH value when samples collected at 6:00am (fasting), 12:00pm and at 18:00pm. TSH shows a diurnal variation. Its concentration is affected by circadian rhythm. TSH concentrations are low during the daytime, increase in the evening, and peak shortly before sleep. TSH is released in pulses every 60-90 minutes over the course of the day. The half life of TSH may vary between different individuals. Conclusion: It is recommended that while evaluating TSH status timed sample should be collected preferably in fasting state. The practice of collecting fasting sample usually happens in the morning, which eliminates known variation of thyroid hormone levels later in the day.
KEYWORDS: Circadian; Pulses; metabolic; hypothyroidism; fasting.
REFERENCES
1.Azukizawa M, Pekary AE, Hershman JM, Plasma thyrotropin, thyroxine and triiodithyronine relationships in man. J Clin Endocrinol Metab 1976;43:53 35-42.
2.Parker DC, Pekary AE, Hershman JM Effect of normal and reversed sleep-wake cycle upon nyctohereral rhythmicity of plasma thyrotropin: Evidence suggestive of inhibitory influence of sleep. J Clin Endocrinol Metab 1976;43:318-329.
3.Week J, Gundersen HJG, Circadian and 30 minutes variation in serum TSH and thyroid hormones in normal subjects. (Copenh) 1978;89:659-672.
4.Samuals MH, Veldhuis JD, Henry P, Ridgway EC Pathophysiology and co-pulsatile release of thyroid stimulating hormone, leutinizing hormone, follicle stimulating hormone, and subunit. J Clin Endocrinol Metab 1990;71:425-432.
5.Rose SR. Nisula BC. Circadian variation of thyrotropin in childhood. J Clin Endocrinol Metab 1989;68:1086-9.
6.Van Coevorden A, Laurent E, Decoster C, ıerkhofs M, Neve P. VanCauter E, Mockel I. Decreased basal and stimulated thyrotropin secretion in healthy elderly men. J Clin Endocrinol Metab 1989:69:177-85.
7.Van Cauter E, Turek FW. Endocrine and other biological rhythms. In: DeGroot U, Besser M, Burger HG, Jameson IL, Loriaux DL, Marshall JC, et al., eds. Endocrinology, 3rd ed. Philadelphia: WB Saunders, 1995:2487-548.
8.Weeke J, Gundersen HJG. Circadian and 30 minutes variations in serum TSH and thyroid hormones in normal subjects. Acta Endocrinol. (Copenh.) 1978;89:659–72.
9.F. Roelfsema, A. M. Pereira, J. D. Veldhuis et al.,Thyrotropin secretion profiles are not different in men and women,Journal of Clinical Endocrinology and Metabolism, 2009;94(10):3964–3967.
10.Alexander WD et al. Metabolism 1964;13:587.
11.Cochran B, Poucher RL and Marbach EP. Clinical Research. 1964;12:89.
12.Riad A Sulaimani. The effect of Ramdan fasting on thyroid function in healthy male subjects. Nutrition Research 1988; 8(5):549-552
13.Fish LH, Schwartz HL, Cavanaugh J, Steffes MW, Bantle JP, Oppenheimer JH, Replcemane dose metabolism , and bioavailability of levothyronine in the treatment of hypothyroidism: role of triidothryronine in pituitary feedback in humans. NEJM 1987;316:764-770.
14.Feldt-Rasmmussen U, Petersen PH, Blaabjerg O, Horder M. Long-term variability in serum thyroglobulin and thyroid related hormones in healthy subjects. Acta Endocrinol (Copenh) 1980;95;328-334.
15.Maes M, Mommen K, Henrickx D, Peeters D'Hondt, P, Ranjan R, De Meyer F, Scharpe S. Components biological variation, including seasonability, in blood concentration of TSH, TT4, FT4, PRL, Cortisol and testosterone in healthy volunteers. Clin Endocrinol (Oxf) 1997; 46:587-598.
16.Andersen S, Bruun NH, Pedersen KM, Laurberg P Biological varation is important for interpretation of thyroid function test. Thyroid 2003;13:1069-1078.
17.Martin I Surks, Gayotri Goswami and Gilbert H. Daniels. Controversy in clinical endocrinology. The thyrotropin reference range remain unchanged. The Journal Of Clinical Endocrinology & Metabolism. 2005;90(9):5489-5496.
18.Brabant G, Prank K, Ranft U, Schuemmeyer T, Wagner TOF, Hasur H, Kummer B, Feistner H, Hesch RD, von zur Muhlen A. Physiological regulation of circadian and pulsatile thyrotropin secretion in normal man and women. J Clin Endorinol Metab 1990;70:403-409.
19.Gary KA, Winokur A, Douglus SD, Kapoor S, Zaugg L, Dinges DF. Total sleep deprivation and the thyroid axis: effects of sleep and waling activity. Aviat Space Environ Med 1996;67:513-519.
20.Buxton OM, Frank SA, L'Hermite-Baleriaux M, Leproult R, Turek FW, van Cauter E. Roles of intensity and duration of nocturnal exercise in causing phase delays of human circadian rhythms. Am J Physiol 1997;36E536-E542.
21.Scobbo RR et al. TSH variability in normal individuals. The influence of time of sample collection W V Med J. 2004;100:138-142.
22.Weeke J, Gundersen HJG. Circadian and 30 minutes variations in serum TSH and thyroid hormones in normal subjects. Acta Endocrinol. (Copenh.) 1978;89:659–72.
23.The thyroid Pathophysiology and Thyroid Function Testing. (Edited) Burtis Ashwood, Bruns. Tietz's Textbook of Clinical Chemistry and Molecular Diagnostics (5th Edition) W. B. Saunders Company 2011. p1930.
24.Keenan DM, Roelfsema F, Biermasz N, Veldhuis JD. Physiological control of pituitary hormone secretory burst mass, frequency and waveform a statistical formulation and analysis. Am J Physiol Regul Integr Comp Physiol 2003;3R664-73.
25.Fares F; The role of O-linked and N-linked oligosaccharide on the structure-function of glycoprotein hormens: development of agonist and antagonist. Biochem Biophys Acta 2006;4:560-7
26.Persani L, Borgato S, Romoli R, Asteria C, Pizzocro A, Beck-Peccoz P. Changes int he degreeof sialylationof carbohydrate chanins modify the biological properties of circulation thyrotropin isoforms in various physiological and pathological states. J Clin Endocrinol Metab 1998;7:2486-92.
27.Kanabrocki EL, Sothern RB, Scheving LE, Vesely Dl, Tsai TH, Shelstad J, et al. Reference value foe circadian rhythems of 98 variables in clinically healthy men in the fifth decade of life. Chronobiol Int 1990; 22:701-9.
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © 2014 Warade J, Pandey A.This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Source of support: None
Original article
Rupal Samal 1 MD DNB(OBG), Sendhil Coumary.A2,* MD, DNB, MNAMS (OBG), Lopamudra B John3 MD, DNB (OBG), Seetesh Ghose4 MD, FICOG
Affiliation:-
1Assistant Professor,2Professor, 3Associate Professor, 4Professor and Head of Department, Department of Obstetrics and Gynaecology, Mahatma Gandhi Medical College And Research Institute, Puducherry, India
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Obstetrics and Gynaecology, Mahatma Gandhi Medical College and Research Institute, Puducherry, India
Address reprint requests to
Dr. Sendhil Coumary. A,
Department of Obstetrics and Gynaecology, Mahatma Gandhi Medical College And Research Institute, Pillaiyarkuppam, Puducherry, India-607402
Article citation:
Samal R, Coumary SA, John LJ, Ghose S. Comparative study of oral, rectal misoprostol with intravenous methylergometrine in active management of third stage of labour. J Pharm Biomed Sci. 2014; 04(09):828-833. Available at www.jpbms.info
ABSTRACT
Objectives: To compare the efficacy and side effects of oral misoprostol, rectal misoprostol and intravenous methyl ergometrine in active management of third stage of labour.
Study Design: Prospective Randomised Control Study.
Study Setting: The study was conducted in Mahatma Gandhi Medical College and Research Institute, Puducherry, between November 2010 and May2012.
Method: 300 participants were randomised into three groups. Active management of third stage of labour was followed in all the participants. The uterotonic of choice divided them into groups. Group I received 0.2 mg methyl ergometrine, Group II received oral misoprostol 400 μg, and Group III received rectal misoprostol 800 μg within one minute of the delivery of the baby. Duration of third stage of labour was noted. Blood loss was measured by preweighed sponge method. Hemoglobin and hematocrit were measured 24 hours after delivery.
Outcome Measures: The parameters studied were the duration of third stage, amount of blood loss in the third stage and side effects of the drugs.
Results: The duration of third stage of labour and blood loss was significantly reduced in group III (rectal misoprostol) with p value<0.001. The difference in haemoglobin and hematocrit measured 24 hours postpartum was also significantly lesser in group III. The incidences of side effects were significantly more in group II.
Conclusion: Rectal misoprostol is an effective uterotonic and an acceptable alternative uterotonic in the Active management of the third stage of labour.
KEYWORDS: Active management of third stage labour; oral misoprostol; rectal misoprostol; methyl ergometrine; duration of third stage.
REFERENCES
1.World Health Organisation (WHO) Department of Reproductive Health and Research. Maternal mortality in 2000: Estimates developed by WHO, UNICEF,
and UNFPA.Geneva: WHO March, 2012.
2.Vora KS,Dileep VM,Ramani KV et al. Maternal Health Situation in India: A Case Study. J Health Popul Nutr. 2009 April; 27(2): 184–201.
3.Obstetrical Haemorrhage: Gray Cunningham et al. Williams Obstetrics 23rd edition. Alyssa Friedband Karen Davis editors. United State of America; Mc Graw Hill; 2010;35:759-761.
4.Placental cord drainage after vaginal delivery as part of the management of the third stage of labour (Review)Copyright © 2011: The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.:2-3
5.Rogers J, Wood J, McCandlish R, Ayers S,Truesdale A, Elbourne D. Active versus expectant management of third stage of labour: the Hinchingbrooke randomised controlled trial. Lancet 1998; 351: 693–99.
6.Maughan KL, Heim SW, Galazka SS. Preventing postpartum hemorrhage: managing the third stage of labor. Am Fam Physician. 2006;73(6):1025–8.
7.Bamigboye AA, Holfmeyr GJ, Merrell Da, Mitchell Ronald. Randomised comparison of rectal misoprostol with syntometerive for mangement of third stage of labour. Acta obstet Gynecol scand 1998;77:178-181.
8.Frederic Amant, Bernard Spitz, Dirk Timmer Man, Annick Corremans, Frans Andre VA . Misoprostol compared with methyle ergometerine for the prevention of PPH a double blind randomized trial. Br J of Obstet and Gynecol .Oct 1999; 106: 1066 – 1070.
9.Parsons SM, Robert LW, Joan MG, et al. Rectal Misoprostol Versus Oxytocin in the Management of the Third Stage of Labour.J Obstet Gynaecol Can 2007; 29(9):711–718.
10.Parsons SM, Robert LW, Joan MG, et al. Oral Misoprostol versus Oxytocin in the Management of the Third Stage of Labour. J Obstet Gynaecol Can 2006; 28(1):20–26.
11.Tripti N , Balram S. 400μg oral misoprostol versus 0.2mg intravenous methyl ergometrine for the active management of third stage of labor. J Obstet Gynecol.2009; 59(3):228-234.
12.Gohil JT, Tripathi Beenu . A study to compare the efficacy of misoprostol, oxytocin, methyl ergometrine and ergometrine-oxytocin in reducing blood loss in active management of third stage of labor. J Obstet Gynecol2011; 61(4):408-412.
13.Surbek VD, Peter MF, Irene H ,Wolfgang H. Oral misoprostol in third stage of labour:A randomised placebo controlled trial. Am J Obstet Gynecol.1999;94(2):255-258.
14.Lumbiganon P, Hofmeyr GJ, Gulmezoglu AM, Pinol A, Villar J. Misoprostol dose related shivering and pyrexia in the third stage of labour. Br J Obstet Gynecol.1999;106:304-308.
15.Chan ASM, Ng PS ,Sin WK,Tang LCH, Cheung KB, Yuen PM. A multicenter randomised controlled trial of oral misoprostol and intramuscular syntometrine in the management of the third stage of labour. J Human Reprod 2001;16(1):31-35.
16.WHO Multi Center randomized trial in the management of the third stage of labour .The Lancet 2001; 358:689-95.
17.Hofmeyr JG. A randomised placebo controlled trial of oral misoprostol in the third stage of labour. Br J Obstet Gynecol 1998; 105:971-975.
18.Walley RL,Wilson JB,Crane JMG,Mathews K,Elizabeth S,Hutchens D. A double blind placebo controlled randomised trial of misoprostol and oxytocin in the management of third stage of labour. Br J Obstet Gynecol.2000;107(9):1111-1115.
Copyright © 2014 Samal R, Coumary SA, John LJ, Ghose S.This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Research article:
Delgado, E.A.D.1, Fonseca JR., J.H.2, Gibertoni, F.2, Beretta, A.L.R.Z3,*
Affiliation:-
1Student-Specialization in Clinical Analysis University Center Hermínio Ometto (UNIARARAS) Araras, S.P.
2Masters Student - Graduate Program - Biomedical Sciences Center Hermínio Ometto (UNIARARAS), Araras, S.P.
3* Doctor-teacher of the Graduate Program in Biomedical Sciences, University Center Hermínio Ometto (UNIARARAS), Araras, SP, Brasil
The name of the department(s) and institution(s) to which the work should be attributed:
Microbiological Research Laboratory, Av. Dr. Maximiliano Baruto, 500 Jd. Universitário. 13607-339 - Araras – SP – Brasil
Address reprint requests to
Ana Laura Remédio Zeni Beretta
Microbiological Research Laboratory, Av. Dr. Maximiliano Baruto, 500 Jd. Universitário. 13607-339 - Araras – SP – Brasil
Article citation:
Delgado, E.A.D., Fonseca JR., J.H., Gibertoni, F., Beretta, A.L.R.Z. Biosafety and the tuberculosis in units of health. J Pharm Biomed Sci. 2014; 04(09):769-772. Available at www.jpbms.info
ABSTRACT
Tuberculosis is an infectious disease of worldwide extent, caused by Mycobacterium tuberculosis and its transmission has always been a frequent concern in healthcare services. With the growth of strains resistant to first-line antituberculosis drugs and the emergence of Acquired Immune Deficiency Syndrome have made this more intense concern.
Objectives: Through exploratory study of articles and books published in the databases LILACS, MEDLINE, thesis database, aimed to identify the risks of health professionals for the occurrence of pulmonary tuberculosis and demonstrate the behaviors of these biosafety professionals exposed to M. tuberculosis.
Results: Due to the large number of infected people and the high risk of movement of persons affected by the disease, biosecurity should function as an effective ally, through action plans and control in health care institutions.
Conclusion: Based on the data, the study suggests that health professionals are at risk because of the limitations found with regard to preventive measures, especially the delayed diagnosis of tuberculosis. It is extremely important to implement biosecurity measures in health facilities, as well as the investigation of pulmonary tuberculosis, since these professionals are unaware of the occupational risks.
KEYWORDS: Pulmonary tuberculosis, health professionals, occupational risk; Biosafety.
REFERENCES
1.Addis Alene K, Nega A, Wasie Taye B. Incidence and predictors of tuberculosis among adult people living with human immunodeficiency virus at the University of Gondar Referral Hospital. Northwest Ethiopia. BMC Infect Dis. 2013:13:292.
2.Barroso, WJ. Biossegurança em tuberculose na unidade de saúde no laboratório. Bol. Pneumol. Sanit. 2014:9(2):27-32.
3.Brasil. Ministério da Saúde. Manual de recomendações para o Controle da Tuberculose no Brasil. Brasília: MS; 2010.
4.Brasil. Ministério da Saúde. Boletim Epidemiológico da Secretaria de Vigilância em Saúde. Ministério da Saúde. 2012:v. 43.
5.Brunello ME, Cerqueira DF, Pinto IC, Arcênio RA, Gonzales RI, Villa TC, et al. Interaction between patient and health care professionals in the management of tuberculosis. Acta Paul Enferm 2009:22(2):176-82.
6.Galesi, VM.N.; Almeida, MMMB. Indicadores de morbimortalidade hospitalar de tuberculose no Município de São Paulo. Revista Brasileira de Epidemiologia, São Paulo,2007;10(1):48-55. Disponível em: <http://www.scielo.br/ pdf/rbepid/v10n1/05.pdf >. Acesso em: 01 mar. 2012.
7.Gonçalves MJ, Ferreira AA: Factors associated with length of hospital stay among HIV positive and HIV negative patients with tuberculosis in Brazil. PLoS One 2013:8(4):e60487.
8.Guimarães, NB; Pereira, PM.; Guimarães, ROB. Estudo clínico- epidemiológico e laboratorial de pacientes co-infectados por tuberculose e aids. Revista 9. Paraense de Medicina, Belem.2009;23,(3), jul.-set. 2009. Disponível em: < http://files.bvs.br/ upload/S/0101-5907/2009/v23n3/a1964.pdf>. Acesso em: 20 nov. 2011.
9.Kritshi, AL et al. Two decades of research on tuberculosis in Brazil: State of the art of scientific publications. Revista de Saúde Pública, Rio de Janeiro. 2007;41, sup. 1:9-14.
10.Maciel EL, Prado TN, Fávero JL, Moreira TR, Dietze R. Tuberculosis in health professionals: a new perspective on an old problem. J Bras Pneumol. 2009:35(1):83-90.
11.Prado TN, Galavote HS, Brioshi AP, Lacerda T, et al. Perfil epidemiológico dos casos notificados de tuberculose entre os profissionais de saúde no Hospital Universitário em Vitória (ES) Brasil. J Bras Pneumol 2008;34(8):607- 613.
12.Ramos I, Souza FBA, Oliveira AB. A biossegurança em tuberculose pulmonar e a prática de enfermagem em um hospital universitário do Rio de Janeiro, Brasil. Rev. de Pesq.: cuidado é fundamental Online. 2010: jan/mar. 2010;2(1):639-645.
13.Santos, MLSG. et al. A dimensão epidemiológica da co-infecção TB/HIV. Rev. Latino-Am. Enfermagem, Ribeirão Preto. 2009:17:5.
14.Souza SR. Biossegurança em tuberculose e os profissionais de enfermagem do Hospital Universitário Clementino Braga Filho da UFRJ [dissertação]. Brasília: Universidade de Brasília; 2009.
15.World Health Organization: Global Tuberculosis Control: WHO Report 2010.
Copyright © 2014 Delgado, E.A.D., Fonseca JR., J.H., Gibertoni, F., Beretta, A.L.R.Z. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript
Original article
Niraj Kumar Biswas1,*,Parimal H Patel2,Hitesh R Ahir3,Purvi H Kothadia3,Alka B Nerurkar4
Affiliation:-
1Associate Professor, 2Assistant Professor, 3Tutor,4Professor and Head, Department of Microbiology, GMERS Medical College, Valsad, Gujarat, India
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Microbiology, GMERS Medical College, Valsad,Gujarat, India
Address reprint requests to
Dr.Niraj KUmar Biswas.
Associate Professor, Department of Microbiology, GMERS Medical College, Valsad, Gujarat, India
Article citation:
Biswas NK,Patel PH,Ahir HR,Kothadia PH,Nerurkar AB. Bacteriological profile of Urinary tract infection and its antibiotic susceptibility at tertiary care Hospital, Valsad, Gujarat,India. J Pharm Biomed Sci. 2014; 04(09):751-754. Available at www.jpbms.info
ABSTRACT
Objective:This study was done to find out the common bacteria causing UTI and to determine the antibiotic susceptibility pattern of the urinary pathogens in patients attending a tertiary care hospital in Valsad, Gujarat.
Material and Methods: In duration of January to July 2014, 179 urine samples were collected from patients of suspected UTI, Collected samples were inoculated on sheep Blood agar, Mac Conkey agar and Nutrient agar and incubated at 37°C by using standard method and antibiotic susceptibility test were performed by Kirby Bauer disc diffusion method.
Results: 76(42.45%) samples were found to be positive in a culture in which 60 (78.95%) were gram negative, 13(17.10%) were Gram positive and 3 (3.95%) were candida spp. Maximum number of organisms isolated were E.coli, followed by Klebsiella sp., Pseudomonas sp. Enterococcus sp, Candida and other organisms. Isolated organisms show more resistance to commonly used antibiotics.
Conclusion: Gram negative bacilli are the commonly isolated organisms in UTI and E.coli is most common of them. An isolated organism shows more resistance to commonly used antibiotics.
KEYWORDS: UTI; Antibiotic susceptibility; urinary pathogens.
REFERENCES
1.Ronald AR, Nicolle LE, Stamm E, et al.Urinary tract infection in adults :research priorities and strategies. Int J Antimicrob Agents.2001; 17:343–348.
2.Devanand Prakash and Ramchandra Sahai Saxena.Distribution and Antimicrobial Susceptibility Pattern of Bacterial Pathogens Causing Urinary Tract Infection in Urban Community of Meerut City, India. ISRN Microbiology, vol. 2013, Article ID 749629, 13 pages, 2013.doi:10.1155/2013/749629.
3.Surinder Kumar. Textbook of Microbiology 1st edition
4.B.Foxman and P. Brown, Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs.Infectious Disease Clinics of North America.2003; 17(2):227–241.
5.Sefton AM. The impact of resistance on the management of urinary tract infections. Int J Antimicrob Agents.2000;16:489–491.
6.Ahmed SM, Avasara AK. Urinary tract infections (UTI) among adolescent girls in Karimnagar District, AP K.A.P STUDY. STUDY Indian J Pre Soc Med.2008;39:12–5.
7 Omoregie R, Erebor JO, Ahonkhai I, Isobor JO, Ogefere HO. Observed changes in the prevalence of uropathogens in Benin City, Nigeria. NZJ Med Lab Sci. 2008;62:29–31.
8.Omoregie R, Eghafona NO. Urinary tract infection among asymptomatic HIV patients in Benin City. Nigeria. Br J Biomed Sci. 2009;66:190–3.
9.J. I. Alós, Epidemiology and etiology of urinary tract infections in the community. Antimicrobial susceptibility of the main pathogens and clinical significance of resistance,” Enfermedades Infecciosas y Microbiología Clínica.2005;23,(4):3–8.
10.Water G,Harrison B,and Kunin G. Urinary tract infection. N.Eng Med.1996; 248-250.
11.Ritu aggrawal,Maneesh Goyal,Dakshina Bisht,Rinku garg. Bacterial isolates and their antibiotic sensitivity profile recovered from urine samples in NCR,Ghaziabad (U.P) JEMDS 2014;3(28):7831-7836.
12.Sharma I,Paul D. Prevalence of community acquired urinary tract infection in Silchar medical college Assam,India and its antimicrobial susceptibility profile. Indian J Med sci 2012;66: 273-279.
13.Sabra SM and Abdel-Fattah MM.Epidemiological and microbiological profile of nosocomial infection in Taif Hospitals,KSA.World journal of medical sciences. 2012;7(1):1-9.
14.Shamataz Razak, Vishwanath Gurushan tappa, Bacteriology of urinary tract infections and antibiotic susceptibility pattern in Tertiary care hospital in south India. IJMSPH 2012; 1(2):109-112.
15.Khameneh ZR, Afshar AT.Antimicrobial susceptibility pattern of urinary tract pathogen. Saudi J Kidney Disease Transpl.2009,20:251-253.
16.Bashir MF, Quazi Ji, Ahmad N, Riaz S. Diversity of urinary tract pathogen and drug resistant isolates of Esch.coli in different age and gender group of Pakistanis. Tropicl J of pharmaceutical research. Sept 2000;7(3):1025-1031.
17.Ahmad K, Imaran. Prevalence of antibiogram of uncomplicated lower urinary tract infections in human population of Gilgit, northern area of Pakistan. Pakistan J. Zoo.2008;40(4):295-301.
Copyright © 2014 Biswas NK,Patel PH,Ahir HR,Kothadia PH,Nerurkar AB. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Competing interest / Conflict of interest: None
Review article:
Mwahib Sid Ahmed Mohamed Osman Aldosh*
Affiliation:-
Assistant Professor, Radiological Sciences Department Applied Medical College - Najran University- Kingdom of Saudi Arabia
The name of the department(s) and institution(s) to which the work should be attributed:
Radiological Sciences Department Applied Medical College - Najran University- Kingdom of Saudi Arabia
Address reprint requests to
Dr. Mwahib Sid Ahmed Mohamed Osman Aldosh ,Ph.D
Assistant Professor, Radiological Sciences Department Applied Medical College-Najran University- Kingdom of Saudi Arabia
Article citation:
Mwahib A. Applications of Nanoparticles in Biomedical. J Pharm Biomed Sci. 2014;04(09):743-750. Available at www.jpbms.info
ABSTRACT
The application of nanomaterials for cancer therapy and for early diagnosis of pathologies has received considerable attention in recent years. Particularly in the field of biomedical with extensive applications. The wide interdisciplinary world of Nanoscience was experiencing a strong development during the last years. One exciting topic is the possibility of using nanoscale materials for biomedical applications. The application of nanotechnology to medicine, known as nanomedicine, concerns the use of precisely engineered materials at this length scale to develop novel therapeutic and diagnostic modalities. Recent improvements in engineering at the nanoscale level have lead to the development of a variety of new, novel nanoscale platforms (quantum dots, nanoshells, gold nanoparticles, paramagnetic nanoparticles, carbon nanotubes), which currently are under development and has profoundly studied. The emerging roles of these wide variety of applications, in biomedical imaging and therapeutic are the focus of this research, in addition to describing how nanoparticles can be used for targeted imaging and delivery of therapeutic agents and identify and discuss strategies to circumvent barriers to intratumoral delivery of nanoparticles.
KEYWORDS: Nanoparticles; applications; magnetic resonance imaging; cancer therapy; diagnostic imaging; drug deliver.
REFERENCES
1.R.V.Ramanujan , R. Narayan Magnetic Particles for Biomedical Applications, 2009, Springer,477-491
2.D.Nagesha, V.Torchillin, Multifunctional Magnetic Nanosystems for Tumor Imaging, Targeted Delivery, and Thermal Medicine, 2008, Springer Volume 4, http://dx.doi.org/10.1007/978-0-387-76554-9_13
3.A.J.Cole1 et al, Trends in Biotechnology, Cancer theranostics: the rise of targeted magnetic nanoparticles, 2011;29(7): No.7,323,http://dx.doi.org/10.1016/j.tibtech.2011.03.001
4.An-Hui Lu, E. L. Salabas and F. Schüth, Angew. Chem. Int. Magnetic Nanoparticles: Synthesis, Protection, Functionalization, and Application,.2007;46,:1222– 1244.http://dx.doi.org/10.1002/anie.200602866
5.Alexiou C., Schmidt A., Klein R., Hulin P.,Bergemann C., and Arnold W. Magnetic drug targeting: biodistribution and dependency on magnetic field strength, J. Magn. Magn. Mat.2002;252(1-3):363-366.
6.Kuznetsov A.A., Filippov V.., Alyautdin R.N.,Torshina N.L., Kuznetsov O.A. Application of magnetic liposomes for magnetically guided transport of muscle relaxants and anti cancer photodynamic drugs. J. Magn. Magn. Mat. 2001;225 (1-2):95-100. 7.Bulte J.W.M., de Cuyper M., Despres D. and Frank J.A. "Preparation, relaxometry, and biokinetics of PEGylated magnetoliposomes as MR contrast agent.J.Magn. Magn. Mat.1999;194(1-3):204-209.
8.Pardoe H., Clark P.R., St Pierre T.G., Moroz P., Jones S.K. A magnetic resonance imaging based method for measurement of tissue iron concentration in liver arterially embolized with ferrimagnetic particles designed for magnetic hyperthermia treatment of tumors,Magnetic Resonance Imaging.2003;21(5):483-488.
9.Jordan A., Scholz R., Maier-Hauff K., Johannsen M., Wust P., Nadobny J., Schirra H., Schmidt H., Deger S., Loening S., Lanksch W. and Felix R. Presentation of a new magnetic field therapy system for the treatment of human solid tumors with magnetic fluid hyperthermia. J. Magn. Magn. Mat.2001; 225(1-2): 118-126.
10.Gruttner C., Rudershausen S. and Teller J. Improved properties of magnetic particles by combination of different polymer materials as particle matrix, J. Magn. Magn. Mat. 2001;225(1-2):1-7.
11.Pardoe H., Chua-anusorn W., St Pierre T.G. and Dobson J. Structural and magnetic properties of nanoscale iron oxide particles synthesized in the presence of dextran or polyvinyl alcohol. J.Magn. Magn. Mat. 2001;225 (1-2):41-46.
12.Ziolo R.R Self-stabilized aqueous ferrofluids. Properties and characteristics. European Cells and Materials,3:92-9.
13.Kratschmer W., Lamb L.D., Fostiropoulos K.and Huffman D.R. Solid C-60 - A new form of carbon, Nature.1990;347:354-358.
14.Cadek M., Murphy R., McCarthy B., Drury A., Lahr B., Barklie R.C., Panhuis M., Coleman J.N. and Blau W.J. Optimisation of the arc-discharge production of multi-walled carbon nanotubes. Carbon. 2002;40(6): 923-928.
15.Goldberg SN, Bonn J, Dodd G, et al. Society of Interventional Radiology Interventional Oncology Task Force: interventional oncology research vision statement and critical assessment of the state of research affairs. J Vasc Interv Radiol. 2005;16(10): 1287–1294.
16.Lim ZZ, Li JE, Ng CT, Yung LY, Bay BH. Gold nanoparticles in cancer therapy. Acta Pharmacol Sin. 2011;32:983-90.
17.Power S, Slattery MM, Lee MJ. Nanotechnology and its relationship to interventional radiology. Part I: imaging. Cardiovasc Intervent Radiol. 2011; 34(2): 221–226.
18.Power S, Slattery MM, Lee MJ. Nanotechnology and its relationship to interventional radiology. Part II: drug delivery, thermotherapy, and vascular intervention. Cardiovasc Intervent Radiol 2010 Sep 16. [Epub ahead of print]
19.Nanoparticles as fluorescent labels for optical imaging and sensing in genomics and proteomics. Anal Bioanal Chem 2011; 399(1):29–42.
20.Yang X Interventional molecular imaging. Radiology 2010; 254(3):651–654.
21.Optical molecular imaging and its emerging role in colorectal cancer. Am J Physiol Gastrointest Liver Physiol.2010; 299(4):G807–G820.
22.Nanoparticles as vehicles for delivery of photodynamic therapy agents. Trends Biotechnol 2008;26(11):612–621.
23.Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine 2008; 3(2):133–149.
24.The potential risks of nanomaterials: a review carried out for ECETOC. Part Fibre Toxicol 2006;3:11.
25.Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65(1–2):271–284.
26.Gohongi T, Fukumura D, Jain RK Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1999; 1: 241–263.
27.Monsky WL, Mouta Carreira C, Tsuzuki Y,Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumors. Clin Cancer Res 2002; 8(4):1008–1013.
28.Al-Abd AM, Hong KY, Song SC, Kuh HJ. Pharmacokinetics of doxorubicin after intratumoral injection using a thermosensitive hydrogel in tumor-bearing mice. J Control Release 2010; 142(1): 101–107.
29.Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol 2003; 5(2):79–88.
30.Germani G, Pleguezuelo M, Gurusamy K,.Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol 2010; 52(3):380–388.
31.Rapoport N, Gao Z, Kennedy A. Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. J Natl Cancer Inst 2007;99(14):1095–1106.
32.Eisenhauer EA, Therasse P, Bogaerts J, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45(2):228–247.
33.Seibel RM, Melzer A, Schmidt A, Plabetamann J. Computed tomography- and magnetic resonance imaging: guided microtherapy. Semin Laparosc Surg 1997; 4(2):61–73.
34.Gadaleta CD, Ranieri G. Trans-arterial chemoembolization as a therapy for liver tumours: new clinical developments and suggestions for combination with angiogenesis inhibitors. Crit Rev Oncol Hematol 2010 Nov 8. [Epub ahead of print].
35.Husseini GA, Pitt WG. Micelles and nanoparticles for ultrasonic drug and gene delivery. Adv Drug Deliv Rev 2008; 60(10):1137–1152.
36.Li X, Li R, Qian X, et al. Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate. Eur J Pharm Biopharm 2008; 70(3):726–734.
37.Lesinski GB, Sharma S, Varker KA,.Release of biologically functional interferon-alpha from a nanochannel delivery system. Biomed Microdevices 2005;7(1):71–79.
38.Damascelli B, Cantù G, Mattavelli F,Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): phase II study of patients with squamous cell carcinoma of the head and neck and anal canal—preliminary evidence of clinical activity. Cancer 2001;92(10):2592–2602.
39.Sheth RA, Mahmood U. Optical molecular imaging and its emerging role in colorectal cancer. Am J Physiol Gastrointest Liver Physiol 2010;299(4): G807–G820
40.Majoros IJ, Myc A, Thomas T, PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. Biomacromolecules 2006;7(2): 572–579.
41.Cormode DP, Skajaa T, Fayad ZA,Mulder WJ. Nanotechnology in medical imaging: probe design and applications. Arterioscler Thromb Vasc Biol 2009;29(7):992–1000.
42.Winter PM, Caruthers SD, Kassner A, et al. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res 2003; 63(18):5838–5843.
43.Villanueva FS, Jankowski RJ, Klibanov S, et al. Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells. Circulation 1998; 98(1):1–5.
44.Coto-García AM, Sote González E, Fernández-Argüelles MT, Nanoparticles as fluorescent labels for optical imaging and sensing in genomics and proteomics. Anal Bioanal Chem 2011; 399(1): 29–42.
45.Sheth RA, Mahmood U. Optical molecular imaging and its emerging role in colorectal cancer. Am J Physiol Gastrointest Liver Physiol 2010;299(4):G807–G820.
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclosure forms provided by the authors are available with the full text of this article at jpbms.info
Copyright © 2014 Mwahib A. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.